In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Deficiency in milk fat globule-epidermal growth factor 8 delays thrombus resolution

Session Basic mechanisms of pulmonary disease

Speaker Thomas Hofbauer

Event : ESC Congress 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure – Pathophysiology and Mechanisms
  • Session type : Moderated Posters

Authors : TM Hofbauer (Vienna,AT), A Alimohammadi (Vienna,AT), J Altmann (Vienna,AT), S Sharma (Vienna,AT), AS Ondracek (Vienna,AT), R Sadushi-Kolici (Vienna,AT), V Seidl (Vienna,AT), A Mangold (Vienna,AT), IM Lang (Vienna,AT)

TM Hofbauer1 , A Alimohammadi1 , J Altmann1 , S Sharma1 , AS Ondracek1 , R Sadushi-Kolici1 , V Seidl1 , A Mangold1 , IM Lang1 , 1Medical University of Vienna, Cardiology - Vienna - Austria ,



Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by the obstruction of pulmonary vessels by organized thrombotic and fibrotic lesions.  Efferocytosis refers to the engulfment of apoptotic cells (ACs) by phagocytes, a process that is facilitated by bridging proteins.  Milk fat globule-epidermal growth factor 8 (MFG-E8) connects phosphatidylserine on ACs with integrin alpha-v beta-III on phagocytes.  MFG-E8-deficient mice develop auto-immune disease closely resembling systemic lupus erythematosus.  In humans, decreased MFG-E8 levels were observed in patients with coronary heart disease and chronic obstructive pulmonary disease.  Whether defective efferocytosis is involved in failure to resolve thrombi in CTEPH remains unknown.


We aimed to assess whether deficiency in MFG-E8 is responsible for of chronic non-resolving thrombosis in CTEPH.


We employed a murine model of chronic thrombosis by inferior vena cava ligation, in MFG-E8 knockout (KO) or wild-type (WT) mice to assess thrombus formation and resolution.  Thrombus size at days 3, 7, 14 and 28 after ligation was assessed using either histologic trichrome stainings (n=4-13 per group and time point) or in vivo high-frequency ultrasound (n=10 per group and time point).  We furthermore recruited CTEPH patients (n=60, 53% female, mean age 56±11 years) and sex- and age-matched healthy controls for measurement of MFG-E8 plasma levels using ELISA.  In CTEPH patients, hemodynamic measurements were performed.  Human lung specimens harvested during surgery for CTEPH or from healthy controls, and isolated monocytes from whole blood of CTEPH patients or controls were analyzed using RT-qPCR.


We observed substantially increased thrombus volume in MFG-E8 KO mice compared to WT, which persisted until day 14 after ligation.  In human CTEPH patients, MFG-E8 in plasma was increased compared to healthy controls.  Similarly, CTEPH monocytes displayed higher concentrations of MFG-E8 mRNA.  Conversely, MFG-E8 expression of CTEPH pulmonary artery specimens was downregulated.  No correlations between MFG-E8 levels and hemodynamic parameters were observed.


MFG-E8 plays an important role in thrombus resolution.  In CTEPH, dysregulation of efferocytosis via impaired MFG-E8 expression in the pulmonary arteries, might drive persistence of thrombus in pulmonary arteries.  The absence of a correlation between MFG-E8 and hemodynamic measures argues against pressure as a confounder of the observation.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are